Department of Pharmacology, National and Kapodistrian University of Athens, Medical School, 11527 Athens, Greece.
Biomedical Engineering Laboratory, Department of Information Transmission Systems and Material Technology, National Technical University of Athens, School of Electrical and Computer Engineering, 15780 Athens, Greece.
Mol Med Rep. 2018 Jul;18(1):864-876. doi: 10.3892/mmr.2018.9008. Epub 2018 May 11.
Cardiac function is reduced following myocardial infarction (MI) due to myocardial injury and alterations in the viable non‑ischemic myocardium, a process known as cardiac remodeling. The current treatments available for patients with acute MI (AMI) reduce infarct size, preserve left ventricular (LV) function and improve survival; however, these treatments do not prevent remodeling, which can lead to heart failure. The aim of the present study was to investigate the effects of thyroid hormone (TH) treatment following MI in an in vivo rat model. A total of 199 rats were separated into 3 groups: Sham operated and 2 different coronary artery ligation (CAL) groups. Rats subjected to CAL were randomly divided into a further 2 groups 24 h following surgery. The first group received standard rat chow (designated the CAL group), while the second group received food containing 0.05% thyroid powder (designated the CALTH group). The mean daily intake of TH per rat was estimated at 3.0 µg T3 and 12 µg T4. Echocardiography was used to monitor the rats. Large‑scale analysis confirmed the favorable effects of TH treatment following CAL on various parameters of cardiac function. TH treatment reduced LV dilation, and increased global and regional LV function. The development of cardiac hypertrophy was induced and, thus, wall stress was limited. Furthermore, TH treatment improved cardiac geometry, which manifested as an increased sphericity index. Myocardial function, as well as LV dilatation, following CAL and TH treatment was not closely associated with the extent of injury, indicating a novel therapeutic intervention that may alter the course of LV remodeling that typically leads to post‑MI heart failure. Data modelling and regressions may be developed to enable the simulation of the pathophysiological processes that occur following MI, and to predict with accuracy the effects of novel or current treatments that act via the modulation of tissue injury, LV dilation, LV geometry and hypertrophy.
心肌梗死（MI）后由于心肌损伤和存活的非缺血心肌的改变，导致心脏功能降低，这一过程称为心脏重构。目前用于急性心肌梗死（AMI）患者的治疗方法可减少梗死面积、保留左心室（LV）功能并提高生存率；然而，这些治疗方法并不能预防重构，而重构可导致心力衰竭。本研究旨在探讨甲状腺激素（TH）治疗对体内大鼠 MI 模型的影响。共将 199 只大鼠分为 3 组：假手术组和 2 种不同的冠状动脉结扎（CAL）组。手术后 24 小时，CAL 组大鼠被随机分为另外 2 组。第一组接受标准大鼠饲料（命名为 CAL 组），而第二组接受含有 0.05%甲状腺粉的食物（命名为 CALTH 组）。每只大鼠每天摄入 TH 的平均量估计为 3.0µg T3 和 12µg T4。通过超声心动图监测大鼠。大规模分析证实了 TH 治疗对 CAL 后各种心脏功能参数的有利影响。TH 治疗减少了 LV 扩张，并增加了整体和局部 LV 功能。心脏肥大的发展被诱导，从而限制了壁应力。此外，TH 治疗改善了心脏几何形状，表现为增加的球形指数。CAL 和 TH 治疗后心肌功能和 LV 扩张与损伤程度不密切相关，表明这是一种新的治疗干预措施，可能改变通常导致 MI 后心力衰竭的 LV 重构过程。可以开发数据建模和回归来模拟 MI 后发生的病理生理过程，并准确预测通过调节组织损伤、LV 扩张、LV 几何形状和肥大来发挥作用的新型或现有治疗方法的效果。
